Tumori intestino

Target

Cerca gli articoli con queste parole nel campo target

Azione della melatonina

Cerca gli articoli con riferimento a queste azioni della melatonina

Anno: 1992

Titolo: Neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin as a second-line treatment in metastatic colorectal carcinoma

Riferimento:
Tumori. 1992 Dec 31;78(6):383-7.

Azione della melatonina:
Neuroimmunotherapy with low-dose interleukin-2 and MLT(50mg/day orally), does not seem to be effective in terms of tumor regression in metastatic colon cancer patients pretreated with 5-fluorouracil.

Target:
Interleukin 2 (IL-2) plus MLT.

Anno: 1993

Titolo: Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract

Riferimento:
Br J Cancer.1993 Jun;67(6):1404-7.

Azione della melatonina:
The immunotherapy with low-dose IL-2 plus MLT (50mg/day orally) is a new well tolerated and effective therapy of advanced tumours of digestive tract.

Target:
Interleukin 2 (IL-2) plus MLT.
Titolo: Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results

Riferimento:
Eur J Cancer. 1993;29A(2):185-9.

Azione della melatonina:
Neuroimmunotherapy with low-dose IL-2 and MLT (50mg/day orally) is a biologically active and well tolerated strategy, capable of determining an apparent control of tumour growth in patients with advanced solid neoplasms.

Target:
Interleukin 2 (IL-2) plus .MLT

Anno: 1994

Titolo: A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma

Riferimento:
Br J Cancer. 1994 Jan;69(1):196-9.

Azione della melatonina:
The concomitant administration of MLT (40 mg day orally) may increase the efficacy of low-dose IL-2 subcutaneous therapy.Tumour objective regression rate was 11/41 vs 1/39, P < 0.001.

Target:
Interleukin 2 (IL-2) plus MLT.

Anno: 2002

Titolo: REVIEW: Gastrointestinal Melatonin: Localization, Function, and Clinical Relevance

Riferimento:
Dig Dis Sci. 2002; 47(10): 2336-2348.

Azione della melatonina:
Melatonin prevents ulcerations of gastrointestinal mucosa by an antioxidant action.

Target:
Preventio or treatment of colorectal cancer.
Titolo: Possible involvement of the nuclear RZR/ROR-alpha receptor in the antitumor action of melatonin on murine Colon 38 cancer

Riferimento:
Tumour Biol. 2002 Sep-Oct;23(5):298-302.

Azione della melatonina:
CGP 55644 (antagonist of the nuclear RZR/ROR alpha receptor) given together MLT blocked its pro-apoptotic effect, MLT strongly lowered the P/A ratio (proliferation/apoptosis).

Target:
Oncostatic action.
Titolo: Effects of melatonin and melatonin receptors ligand N-[(4-methoxy-1H-indol-2-yl)methyl]propanamide on murine Colon 38 cancer growth in vitro and in vivo

Riferimento:
Neuro Endocrinol Lett. 2002 Apr;23 Suppl 1:50-4.

Azione della melatonina:
Oncostatic effect of MLT depends on acting via both MT(2) and RZR/ROR nuclear receptors.

Target:
Nuclear orphan receptors ( RZR/ROR).

Anno: 2003

Titolo: Circadian fluctuations of melatonin, tumor necrosis factor-alpha and its soluble receptors in the circulation of patients with advanced gastrointestinal cancer

Riferimento:
J Exp Clin Cancer Res. 2003 Jun;22(2):171-8.

Azione della melatonina:
May suggest the presence of self-regulation mecha-nisms between the neuroendocrine system and the cytokine network in advanced cancer patients.

Target:
Tumor necrosis factor alpha (TNFalpha).
Titolo: Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorour

Riferimento:
Anticancer Res. 2003 Mar-Apr;23(2C):1951-4.

Azione della melatonina:
Concomitant administration of MLT (orally at 20 mg/day) and irinotecan (CPT-11) in patients with metastatic colorectal cancer: partial response (PR) was in 5 out of 14, stable disease (SD) in 7 out of 14, disease-control achieved in patients was 12 out of 14, p < 0.05.

Target:
Antioxidant and immuno-modulating effects.

Anno: 2009

Titolo: Luzindole but not 4-phenyl-2- propionamidotetralin (4P-PDOT) diminishes the inhibitory effect of melatonin on murine Colon 38 cancer growth in vitro

Riferimento:
Neuro Endocrinol Lett. 2009;30(5):657-62.

Azione della melatonina:
Melatonin at (10-7, 10-9 M) significantly decreased the viability of Colon 38 cancer cells.

Target:
Oncostatic action of MLT

Pagine

Created and managed by Capitolium © 2000-2021